Brief: Oasmia Pharmaceutical Q3 Operating Loss Widens To SEK 57.7 Mln

Vivesto AB

27/03/2020 06:52

March 27 (Reuters) - Oasmia Pharmaceutical AB  OASM.ST :
    * Q3 CONSOLIDATED NET SALES AMOUNTED TO TSEK 144 (1,427)
    * Q3 OPERATING LOSS WAS TSEK -57,708 (-26,248)
    * ON CORONAVIRUS: DUE TO THE SITUATION WITH THE COVID 19
VIRUS,
THE COMPANY IS EXPERIENCING A SLOWDOWN IN ITS APEALEA LAUNCH
ACTIVITIES IN SWEDEN, DENMARK AND FINLAND

Source text: https://bit.ly/2xvNkv3
Further company coverage:  OASM.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))